Following reports that 30 people died in Norway after receiving the Pfizer vaccine, the government, its health officers and Pfizer have all been falling over themselves, assuring us the vaccine is safe.
Notwithstanding these assurances, it is imperative that safety concerns be addressed in detail. Professor Paolo Bellavite, of the University of Verona Medical School, whose expertise is in experimental medicine and innate immunity, argues that the Pfizer vaccine clinical trials concluded far too soon.
Already a subscriber? Log in
Subscribe for just $2 a week
Try a month of The Spectator Australia absolutely free and without commitment. Not only that but – if you choose to continue – you’ll pay just $2 a week for your first year.
- Unlimited access to spectator.com.au and app
- The weekly edition on the Spectator Australia app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Comments
Don't miss out
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
SUBSCRIBEAlready a subscriber? Log in